with marijuana maker Cronos to churn out similar ingredients, including those present only in very low quantities in the cannabis plant such as THCV.Little is known publicly about Lavvan, but its new CEO, Etan Bendheim, took on the role after a 10-year run at livestock pharmaceutical company Phibro Animal Health, where he served most recently as its director of strategy.
The deal between Amyris and Lavvan includes research and development, milestone payments, plus long-term royalties. It also includes the rights to manufacture 20 different compounds in the marijuana plant, Melo said. For now, they will aim to start churning out CBD.One potential obstacle that Amyris could face is demonstrating that their scientific approach to sweetener and skincare works with cannabis. Melo is optimistic, however.
ایران آخرین اخبار, ایران سرفصلها
Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.
منبع: NBCNews - 🏆 10. / 86 ادامه مطلب »
منبع: Forbes - 🏆 394. / 53 ادامه مطلب »